Page 2 - வாஸ்குலர் ஆராய்ச்சி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from வாஸ்குலர் ஆராய்ச்சி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In வாஸ்குலர் ஆராய்ச்சி Today - Breaking & Trending Today

Going Against Guidelines—Nearly 50% of PAD Patients Do Not Receive Statin Therapy

ACC: VOYAGER-PAD Makes Case for Rivaroxaban | Physician's Weekly


Jan 1, 2021
But if rivaroxaban is ’in’, is DAPT ’out’?
The introduction of direct oral anticoagulants (DOACs) in 2010 significantly changed clinical algorithms for prevention of VTE and stroke, as well as management of atrial fibrillation. In this report, which was initially published March 29, 2020, researchers presented findings that support a role for rivaroxaban in revascularization procedures in patients with PAD. BreakingMED is republishing this report as part of its year end clinical review series.
Findings from a trial of more than 6,564 patients undergoing revascularization procedures for peripheral artery disease are likely to change clinical practice, signaling a death knell for dual antiplatelet therapy while boosting the use of direct oral anticoagulant (DOAC) therapy in these patients. ....

Williamr Hiatt , Marcp Bonaca , Peggy Peck , Sahil Parihk , Roxana Mehran , Board Of Trustees , Vascular Research , University Of Colorado Anschutz Medical Campus , Peripheral Vascular Disease Council , Clinical Research , Community Health , World Congress , Vascular Outcomes Study , Surgical Limb Revascularization , Associate Professor , Colorado Anschutz Medical Campus , Cardiology Virtual , New England Journal , Vascular Disease Council , பெக்கி பெக் , ரோக்ஷணா மெஹ்ரான் , பலகை ஆஃப் அறங்காவலர்கள் , வாஸ்குலர் ஆராய்ச்சி , பல்கலைக்கழகம் ஆஃப் கொலராடோ அண்சச்சுட்ஸ் மருத்துவ வளாகம் , புற வாஸ்குலர் நோய் சபை , மருத்துவ ஆராய்ச்சி ,

ARCA biopharma Announces First Patients Enrolled in ASPEN-COVID-19 Phase 2b Clinical Trial ...


Press release content from Globe Newswire. The AP news staff was not involved in its creation.
ARCA biopharma Announces First Patients Enrolled in ASPEN-COVID-19 Phase 2b Clinical Trial .
ARCA biopharma, Inc.December 15, 2020 GMT
rNAPc2 development focused on unmet need for treatments in hospitalized COVID-19 patients, including after availability of vaccines
rNAPc2 is the only novel compound being developed for COVID-19 Associated Coagulopathy
Topline trial data anticipated in the second quarter of 2021
Data from this development program will also inform potential development in additional RNA virus-associated diseases
ADVERTISEMENT
WESTMINSTER, Colo., Dec. 15, 2020 (GLOBE NEWSWIRE) ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that the first patients have been enrolled in ASPEN-COVID-19, the Phase 2b ....

United States , Derek Cole , Wolfram Ruf , Michael Bristow , American Heart Association , Vascular Research , Drug Administration , Exchange Commission , Company On Linkedin , University Of Colorado Hospital On , University Of Colorado School Medicine , Professor At Scripps Research , Clinical Research , Johannes Gutenberg University Medical Center Mainz , Colorado Hospital , Chief Executive Officer , Scientific Director , Scripps Research , Executive Director , Colorado School , Fast Track , Private Securities Litigation Reform Act , Media Contact , ஒன்றுபட்டது மாநிலங்களில் , டெரெக் கோல் , வொல்ஃப்ராம் ரூஃப் ,